KSI-3716 is a potent c-Myc inhibitor that blocks the binding of the c-MYC/MAX complex to target gene promoters; it is used as an effective intravesical chemotherapeutic agent for bladder cancer research; it suppresses tumor growth with minimal systemic toxicity upon intravesical administration.